These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 7492260)

  • 21. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains.
    Noga JT; Hyde TM; Herman MM; Spurney CF; Bigelow LB; Weinberger DR; Kleinman JE
    Synapse; 1997 Nov; 27(3):168-76. PubMed ID: 9329152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction.
    Hirsch SR; Das I; Garey LJ; de Belleroche J
    Pharmacol Biochem Behav; 1997 Apr; 56(4):797-802. PubMed ID: 9130307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia.
    Nakazawa K; Jeevakumar V; Nakao K
    NPJ Schizophr; 2017; 3():7. PubMed ID: 28560253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review.
    Stone JM; Morrison PD; Pilowsky LS
    J Psychopharmacol; 2007 Jun; 21(4):440-52. PubMed ID: 17259207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.
    Oda Y; Fujita Y; Oishi K; Nakata Y; Takase M; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
    Psychopharmacology (Berl); 2017 Oct; 234(20):3027-3036. PubMed ID: 28744562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An integrated view of pathophysiological models of schizophrenia.
    Duncan GE; Sheitman BB; Lieberman JA
    Brain Res Brain Res Rev; 1999 Apr; 29(2-3):250-64. PubMed ID: 10209235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.
    Cohen SM; Tsien RW; Goff DC; Halassa MM
    Schizophr Res; 2015 Sep; 167(1-3):98-107. PubMed ID: 25583246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schizophrenia: Basic and Clinical.
    Coyle JT
    Adv Neurobiol; 2017; 15():255-280. PubMed ID: 28674984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glutamatergic mechanisms in schizophrenia.
    Tsai G; Coyle JT
    Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. D-Aspartate: An endogenous NMDA receptor agonist enriched in the developing brain with potential involvement in schizophrenia.
    Errico F; Mothet JP; Usiello A
    J Pharm Biomed Anal; 2015 Dec; 116():7-17. PubMed ID: 25868730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia.
    Banerjee SP; Zuck LG; Yablonsky-Alter E; Lidsky TI
    Neuroreport; 1995 Dec; 6(18):2500-4. PubMed ID: 8741750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging the glutamatergic system in vivo--relevance to schizophrenia.
    Bressan RA; Pilowsky LS
    Eur J Nucl Med; 2000 Nov; 27(11):1723-31. PubMed ID: 11105831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder.
    Woo TU; Walsh JP; Benes FM
    Arch Gen Psychiatry; 2004 Jul; 61(7):649-57. PubMed ID: 15237077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity.
    Olney JW; Farber NB
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():43-6. PubMed ID: 7961572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The acute effects of NMDA antagonism: from the rodent to the human brain.
    Gunduz-Bruce H
    Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential role of lamotrigine in schizophrenia.
    Large CH; Webster EL; Goff DC
    Psychopharmacology (Berl); 2005 Sep; 181(3):415-36. PubMed ID: 16001126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The GABA-glutamate connection in schizophrenia: which is the proximate cause?
    Coyle JT
    Biochem Pharmacol; 2004 Oct; 68(8):1507-14. PubMed ID: 15451393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Social isolation induces schizophrenia-like behavior potentially associated with HINT1, NMDA receptor 1, and dopamine receptor 2.
    Li BJ; Liu P; Chu Z; Shang Y; Huan MX; Dang YH; Gao CG
    Neuroreport; 2017 May; 28(8):462-469. PubMed ID: 28410269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.